WTW Willis Towers Watson
Quality fee broker, cheaper at 292, but price is still about double book-based value: stay disciplined.
The story
WTW is a top-three global insurance broker and HR/benefits consultant: a fee-based, capital-light franchise with no underwriting balance-sheet risk. Margins recovered to 22.8% after a one-off impairment year (3.7%), and trailing ROE of 19.6% on 7.98B of book sits in line with our 19% normalized view. Heavy buybacks keep book growth modest, and goodwill makes up a large share of that book, which inflates the market-to-book multiple. The stock has fallen from 343 to 292 since our last take, but the fundamentals have not changed.
No facts moved materially, so the drivers are unchanged. Trailing ROE of 19.6% confirms the 19% normalized level, allowing for softening insurance pricing. Buybacks cap book growth at about 4% (3.5% terminal, below the 5.24% risk-free rate). Beta stays near the 0.9 industry anchor, and failure risk stays low for a fee broker.
Value drivers
| Return on equity (normalized) | 19.0% |
| Book-value growth (Y1) | 4.0% |
| Terminal book growth | 3.5% |
| Beta | 0.95 |
| Failure probability | 0.7% |
| Cost of equity | 9.5% |
Valuation bridge
| PV of excess returns | 3.55B |
| PV of terminal excess | 1.54B |
| Equity value | 12.97B |
| ÷ shares → per share | $139.70 |
Projected excess returns on equity
| Yr | Book equity | ROE | Excess return | PV |
|---|---|---|---|---|
| 1 | 7.98B | 19.0% | 756.52M | 690.79M |
| 2 | 8.30B | 18.2% | 717.80M | 598.49M |
| 3 | 8.62B | 17.3% | 674.40M | 513.45M |
| 4 | 8.96B | 16.5% | 626.13M | 435.28M |
| 5 | 9.30B | 15.7% | 572.78M | 363.60M |
| 6 | 9.65B | 14.8% | 514.14M | 298.02M |
| 7 | 10.01B | 14.0% | 450.02M | 238.19M |
| 8 | 10.38B | 13.2% | 380.20M | 183.75M |
| 9 | 10.75B | 12.3% | 304.50M | 134.38M |
| 10 | 11.14B | 11.5% | 222.72M | 89.75M |
Key risks
- Softening P&C pricing cycle compresses organic growth and commission revenue
- Book equity understates economic capital (goodwill, buybacks), so residual income understates value and the model gap may be structural rather than mispricing
- Execution risk on margin expansion and portfolio reshaping (post-TRA sale, Aon/Gallagher/Marsh competition)
Catalysts
- Sustained 23%+ operating margins and mid-single-digit organic growth, lifting normalized ROE above 20%
- Continued large buybacks at the lower share price, boosting per-share returns